Previous 10 | Next 10 |
Rigel Announces Poster Presentations at the 65th American Society of Hematology Annual Meeting and Exposition PR Newswire -- Growing body of data on REZLIDHIA ® (olutasidenib) in mIDH1 relapsed or refractory (R/R) acute myeloid leukemia (AML) patients -- -...
Rigel Announces Conference Call and Webcast to Report Third Quarter 2023 Financial Results and Business Update PR Newswire SOUTH SAN FRANCISCO, Calif. , Oct. 31, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will rep...
Rigel Announces Presentation at the Upcoming IDWeek 2023 PR Newswire -- Provides Update on ACTIV-4 Host Tissue Trial -- SOUTH SAN FRANCISCO, Calif. , Oct. 11, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an upcoming...
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif. , Oct. 6, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Induc...
Rigel to Present at the 2023 Cantor Global Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif. , Sept. 20, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno , the company's chief financial officer, wil...
Rigel to Participate in Upcoming September Investor Conferences PR Newswire SOUTH SAN FRANCISCO, Calif. , Aug. 30, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company's president and chief exe...
2023-08-10 17:46:10 ET Summary Rigel Pharmaceuticals shows growth in Q2 2023 earnings with increased revenues and reduced net loss, but concerns remain over financial stability. The company focuses on expanding hematology/oncology products, showing promise in growth strategies, bu...
2023-08-01 21:58:10 ET Rigel Pharmaceuticals, Inc. (RIGL) Q2 2023 Earnings Conference Call August 01, 2023 04:30 PM ET Company Participants Ray Furey - EVP, General Counsel and Corporate Secretary. Raul Rodriguez - President and CEO Dave Santos - EVP and Chief Co...
2023-08-01 16:30:13 ET Rigel Pharmaceuticals press release ( NASDAQ: RIGL ): Q2 GAAP EPS of -$0.04 beats by $0.04 . Revenue of $26.89M (-9.8% Y/Y) beats by $1.19M . Second quarter 2023 Total Revenue of $26.9 million which includes TAVALISSE net product sal...
Rigel Reports Second Quarter 2023 Financial Results and Provides Business Update PR Newswire Second quarter 2023 Total Revenue of $26.9 million which includes TAVALISSE ® net product sales of $21.3 million and REZLIDHIA ® net product sales of $2.6...
News, Short Squeeze, Breakout and More Instantly...
Rigel Pharmaceuticals Inc. Company Name:
RIGL Stock Symbol:
NASDAQ Market:
Rigel Pharmaceuticals Inc. Website:
2024-06-27 09:02:05 ET Rigel Pharmaceuticals (RIGL) announced stock split at a ratio of 1-for-10 on 2024-06-27 ... Full story available on KlickAnalytics.com
Rigel Announces Reverse Stock Split PR Newswire SOUTH SAN FRANCISCO, Calif. , June 25, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will effect a reverse stock split of its issued and outstanding shares of common st...
Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application PR Newswire GAVRETO will be available from Rigel in the U.S. beginning June 27, 2024 SOUTH SAN FRANCISCO, Calif. , June 24, 2024 /PRNewswire/ -- Rigel Pharmac...